Board Of Directors

Richard B. Bankert V.M.D., Ph.D.

CO-FOUNDER & PRESIDENT

Richard Bankert is the co-founder and has served as the President of Therapyx, Inc. since 2001. Dr. Bankert received both his Veterinariae Medicinae Doctoris (VMD) and his Ph.D. degrees from the University of Pennsylvania and is currently Professor Emeritus in the Department of Microbiology and Immunology at University at Buffalo. An internationally recognized expert in tumor immunology, Dr. Bankert has pioneered the development of the human tumor/SCID mouse xenograft model for studies of human tumor immunity. Dr. Bankert continues to guide the company’s preclinical investigations and the company’s use of novel preclinical modeling of immunity.

Nejat K. Egilmez, Ph.D.

CO-FOUNDER & CHIEF EXECUTIVE OFFICER

Dr. Egilmez is the co-founder of Therapyx, Inc. and serves as the company’s Chief Executive Officer. Dr. Egilmez received his Ph.D. degree from the Department of Cell and Molecular Biology of The State University of New York at Buffalo. He is currently Professor and Chair of the Department of Microbiology and Immunology in the School of Medicine at University of Louisville. Dr. Egilmez’s academic research interests include immune regulation and therapy in cancer and inflammatory diseases. His laboratory pioneered the use of sustained-release nano/microparticulate protein formulations for cancer and inflammatory/infectious disease therapy. Dr. Egilmez directs the company’s research and business efforts.

Kenneth Tramposch, Ph.D.

VICE-PRESIDENT FOR BUSINESS DEVELOPMENT

Dr. Tramposch has over 20 years of experience in drug development and has been involved in the submission of many INDs and NDAs during his professional career in the pharmaceutical industry. One of Dr. Tramposch’s inventions at Bristol-Myers Squibb, for which he led the development team up to IND submission, was approved by the FDA in 1999 as a new drug and is currently marketed under the name Solage. At Pilot Therapeutics, he was responsible for the planning and execution of research and development activities and completed the development of the Company’s first product in 12 months. Dr. Tramposch is the retired Associate Vice-President for Research and Associate Professor of Pharmacology and Toxicology at University at Buffalo.